Health Economics & Market Access

AF Burden of Disease and Treatment

Health Economics & Market Access

AF Burden of Disease and Treatment

As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.

Atrial fibrillation is a chronic and typically progressive disease that significantly impairs patient quality of life and increases their risk of developing co-morbidities.2

AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3

As a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, Biosense Webster, Inc. is committed to patient advocacy and raising awareness of atrial fibrillation and its available treatment options.

Atrial fibrillation is a chronic and typically progressive disease that significantly impairs patient quality of life and increases their risk of developing co-morbidities.2

AF increases a patient’s risk of life-threatening complications, such as stroke, heart attack, and heart failure.2 Patients with AF have a 46% higher risk of mortality than individuals without AF.2,3